Cardiff Oncology (NASDAQ:CRDF) Receives “Buy” Rating from HC Wainwright

Cardiff Oncology (NASDAQ:CRDF)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They presently have a $14.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 297.73% from the stock’s previous close.

Separately, Piper Sandler upped their price target on Cardiff Oncology from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st.

Cardiff Oncology Stock Performance

Shares of Cardiff Oncology stock opened at $3.52 on Monday. The company’s fifty day moving average is $4.57 and its two-hundred day moving average is $2.51. Cardiff Oncology has a 1 year low of $0.94 and a 1 year high of $6.42. The company has a market capitalization of $157.41 million, a P/E ratio of -3.91 and a beta of 2.02.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. Cardiff Oncology had a negative return on equity of 54.54% and a negative net margin of 6,594.92%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.08 million. As a group, equities analysts expect that Cardiff Oncology will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. purchased a new position in Cardiff Oncology in the first quarter worth $1,351,000. Callan Capital LLC grew its holdings in Cardiff Oncology by 37.2% during the 1st quarter. Callan Capital LLC now owns 42,747 shares of the company’s stock valued at $228,000 after buying an additional 11,600 shares during the last quarter. Finally, PFG Investments LLC acquired a new stake in Cardiff Oncology during the 1st quarter valued at $53,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.